Anti-inflammatory therapy for diabetic retinopathy.
Zhang, Wenbo +1,2,3,7; Liu, Hua 1,2; Rojas, Modesto 1,2; Caldwell, Robert W 3; Caldwell, Ruth B 1,2,4,5,6
[Review] Immunotherapy. 3(5):609-628, May 2011.

(Format: HTML, PDF)

: Diabetic retinopathy (DR) is one of the most common complications of diabetes. This devastating disease is a leading cause of blindness in people of working age in industrialized countries and affects the daily lives of millions of people. Despite tight glycemic control, blood pressure control and lipid-lowering therapy, the number of DR patients keeps growing and therapeutic approaches are limited. Moreover, there are significant limitations and side effects associated with the current therapies. Thus, there is a great need for development of new strategies for prevention and treatment of DR. Studies have shown that DR has prominent features of chronic, subclinical inflammation. This article focuses on the role of inflammation in DR and summarizes the progress of studies of anti-inflammatory strategies for DR.

(C) 2011Future Medicine, Ltd.